BACKGROUND: Increased dead-space fraction is common in patients with persistent acute respiratory distress syndrome (ARDS). We evaluated the changes in the oxygenation and dead-space fraction in patients with persistent ARDS after corticosteroid therapy. METHODS: This was a non-randomized non-placebo, controlled observational study including 19 patients with persistent ARDS treated with corticosteroids. We measured P aO 2 /F IO 2 and dead-space fraction at days 0, 4, and 7 after corticosteroids treatment (methylprednisolone) initiation. Patients were classified in intermediate group when corticosteroids were initiated between days 8 -14 after ARDS onset, and in late group when initiated after 14 days. RESULTS: Mean time from the diagnosis of the ARDS to methylprednisolone treatment was 11 ؎ 2 days in the intermediate group (10 patients) and 21 ؎ 8 days in the late group (9 patients). When comparing days 0, 4, and 7 after methylprednisolone treatment, we found an increase in the P aO 2 /F IO 2 (145 ؎ 64 mm Hg, 190 ؎ 68 mm Hg, and 226 ؎ 84 mm Hg, respectively, P < .001) and a decrease in the physiological dead-space fraction (0.66 ؎ 0.10, 0.58 ؎ 0.12, and 0.53 ؎ 0.11, respectively, P < .001). No differences were found between the intermediate and late groups. CONCLUSIONS: In patients with persistent ARDS, the increase in oxygenation was accompanied by a decrease in the dead-space fraction after a few days of corticosteroid treatment. To confirm potential benefit of corticosteroids on physiological parameters and mortality will require a powered randomized placebo controlled trial.
Introduction
Acute respiratory distress syndrome (ARDS) is a complex inflammatory lung injury associated with pulmonary microcirculation abnormalities and capillary thrombosis. [1] [2] [3] [4] [5] Abnormal physiological responses in ARDS include an increase in right-to-left intrapulmonary shunt, an increase in total dead-space fraction, and a reduction of lung compliance. [1] [2] [3] [4] [5] The clinical consequence of these diverse injury responses is impaired oxygenation and ventilation. Persistent ARDS, also known as unresponding ARDS, is characterized by ongoing inflammation and disorganized fibrosis. Clinical manifestations include ongoing hypoxemia, bilateral opacities on the chest radiograph, fever, and leukocytosis, without evidence of infection for 7 or more days after ARDS onset. 2, 6, 7 SEE THE RELATED EDITORIAL ON PAGE 477 The increase in the dead-space fraction is a risk factor associated with increased mortality during the early and intermediate phases of ARDS. 5,8 -11 However, such association was controversial when evaluating the level of hypoxemia and mortality in early ARDS. While some studies showed no association, 5, 12, 13 others found an association of the level of hypoxemia with mortality. 14 -16 Despite the difficulty to translate into survival benefit or long-term ventilator-free days benefit when treatments that improve oxygenation are evaluated, 17 changes in physiological dead-space fraction may be useful in assessing the effectiveness of pharmacologic therapies aimed at reducing inflammation and reversing pulmonary capillaries thrombosis in ARDS. The effect of corticosteroid therapy (an anti-inflammatory agent) on the dead-space fraction of patients with ARDS has not yet been evaluated, despite the fact that this therapy showed a beneficial effect in the oxygenation and a controversial beneficial effect on mortality in the intermediate and late phases of ARDS patients. 7, 18 It has to be noted that similar studies evaluating the potential effect of the administration of activated protein C, which would improve the lung microcirculation and therefore decrease the dead-space fraction in ARDS patients, did not translate into an improvement in survival. 19, 20 This should be the ideal clinical studies end point.
The aim of this study was to evaluate the changes in oxygenation and dead-space fraction in persistent ARDS patients after corticosteroid therapy initiated during the intermediate and late phases.
Methods

Patients
This nonrandomized non-placebo-controlled observational study included 19 patients with ARDS treated with methylprednisolone, who were nonconsecutively admitted in the intensive care unit (ICU) of our tertiary university hospital (Hospital Universitari Son Dureta, Palma de Mallorca, Spain) from February 2005 through December 2008. The study protocol was approved by our institutional review board, and informed consent was obtained from each patient or relatives.
Patients older than 18 years, with endotracheal intubation, receiving invasive mechanical ventilation for acute hypoxemic respiratory failure, who met the AmericanEuropean consensus definition of the ARDS 1 were eligible for the study if they presented:
• A persistent ARDS, defined by remaining bilateral opacities on the chest radiograph and ventilator-dependence due to persistent hypoxemia, a P aO 2 
Management
Patients were mechanically ventilated with a lung-protective strategy during volume controlled mode, using a tidal volume (V T ) of 6 -8 mL/kg of ideal body weight, maintaining plateau pressure less than 33 cm H 2 O, and following the ventilation algorithm of combination of F IO 2 and PEEP described in the ARDS Network low-V T trial. 7 Each patient's clinical management, consideration of persistent ARDS, and the decision to initiate corticosteroid therapy were based on the ICU attending physician's criteria.
A bronchoalveolar lavage or aspirate was performed in all cases prior to corticosteroid treatment initiation, to exclude occult ventilator-associated pneumonia. Patients with documented infection required appropriate antibiotic therapy for at least 3 days prior to corticosteroid treatment.
According to a Meduri et al study, 18 corticosteroid treatment was given with a methylprednisolone loading dose of 2 mg/kg, followed by 2 mg/kg per day from day 1 to day 14, 1 mg/kg per day from day 15 to 21, 0.5 mg/kg per day from day 22 to day 28, 0.25 mg/kg per day on days 29 and 30, and 0.125 mg/kg per day on days 31 and 32. Methylprednisolone was administered at 6-hour intervals (one fourth of daily dose) because the approximate halflife is 180 min. If the patient was extubated between days 1 and 14, the patient was advanced to day 15 of drug therapy and tapered according to the schedule detailed above. 18 
QUICK LOOK
Current knowledge
Elevated dead space to tidal volume ratio in patients with ARDS is associated with increased mortality. The use of steroids in ARDS remains controversial with respect to dose and timing.
What this paper contributes to our knowledge
Methylprednisolone administered to patients with intermediate and late ARDS is associated with improved oxygenation and reduced dead space to tidal volume ratio as early as 4 days following initiation.
Measurement of Dead-Space Fraction and Quasistatic Compliance
Dead-space fraction measurement was made on volume controlled or pressure support ventilation, while the patient was at rest and observed to be reasonably calm and synchronous with the ventilator. 11 We measured the partial pressure of mixed expired carbon dioxide (P ECO 2 ) by collecting expired gas in a Douglas bag for 5 min, during which we also drew an arterial blood sample to measure P aCO 2 . The Douglas bag was placed at the expiratory valve outlet of the ventilator (EVITA 4, Dräger, Lübeck, Germany). We measured P ECO 2 from the Douglas bag, and P aCO 2 from an arterial blood sample, with a blood gas analyzer (IL-1650, Instrument Laboratory, Izasa, Spain). Arterial blood samples were obtained from an indwelling arterial catheter at the mid-point of the 5-min interval. We used a previously described method to correct the P ECO 2 for ventilator circuit compressible volume. 22, 23 The compressible volume value applied to correct P ECO 2 was 2 mL/ cm H 2 O (measured compressible volume was 1.9 -2.1 mL/ cm H 2 O). Tidal volume was not adjusted for the measurement of dead-space fraction. We then calculated the dead-space fraction with the Enghoff modification 24 of the Bohr equation:
Quasistatic respiratory compliance was calculated with standard methods from measurements made during the collection of expired gas. Expired gas was measured with a Wright spirometer. Minute volume (V E ) was calculated by dividing expired gas by collecting minutes, and tidal volume was calculated by dividing V E by respiratory frequency. Quasistatic respiratory compliance was calculated as the value obtained by dividing the difference between the tidal volume (in mL) and the volume compressed in the ventilator circuit (in mL) by the difference between the plateau pressure (in cm H 2 O), measured after a 0.5-second pause at the end of inspiration, and the PEEP (in cm H 2 O) of the ventilator. 5 Patients on pressure support ventilation were changed to volume controlled ventilation for plateau pressure and quasistatic respiratory compliance measurements on the same day.
Corrected V E for P aCO 2 was calculated from V E measured, according to the protocol and methods used by the ARDS Network during the screening from the Late Steroid Rescue Study (LaSRS), 7 using the following formula:
Data Collection and Definitions
The following data were recorded: age, sex, weight, height, comorbidities (eg, diabetes, chronic alcohol abuse, cirrhosis, and malignancy), and severity of illness evaluated by the Simplified Acute Physiology Score II (SAPS II) during the first day of ICU stay 25 and the Sequential Organ Failure Assessment (SOFA) score. 26 The etiology associated with ARDS and the different respiratory parameters of interest were also recorded. According to the pathway of lung injury the ARDS was categorized as direct (via airways), such as occurs in pneumonia, aspiration of gastric contents, or near-drowning, or as indirect (via bloodstream), such as occurs in sepsis, pancreatitis, or severe trauma. 2 The dead-space fraction and other physiological pulmonary variables, such as the P aO 2 /F IO 2 ratio, the level of PEEP, the quasistatic compliance, and opacities on chest radiograph, needed to calculate the lung injury score, 27 were evaluated before methylprednisolone treatment initiation (day 0), and again on days 4 and 7 after corticosteroid therapy initiation in those patients who remained mechanically ventilated. Patients were followed up until they died or until hospital discharge.
Patients were divided in 2 groups according to the length between the diagnosis of ARDS and the initiation of methylprednisolone treatment: intermediate group, when methylprednisolone treatment was initiated between 8 -14 days of ARDS onset, and late group, when methylprednisolone was initiated after 14 days of ARDS onset. 7 
Statistical Analysis
Data are expressed as mean Ϯ standard deviation or median and interquartile ranges for continuous variables and number and percentages for categorical variables as appropriate. Comparisons between intermediate and late groups were made using the independent Student t test or the Mann-Whitney test for continuous data, and with the chi-square or the 2-sided Fisher exact test for categorical data. Comparisons between respiratory parameters in days 0, 4, and 7 after methylprednisolone treatment initiation were made using Friedman 2-way analysis of variance test. We performed the statistical analysis with statistics software (SPSS 15.0, SPSS, Chicago, Illinois).
Results
Nineteen patients were studied: 7 male and 12 female. Fifteen (79%) out of the 19 patients had pneumonia or aspiration (Table 1) , and 16 patients (84%) had septic shock. The mechanism of the ARDS was direct lung injury in 18 (94.7%) of the cases. Bronchoalveolar lavage was performed in 9 patients, and bronchoalveolar aspirate in 10 patients. Positive cultures were found in 3 patients: 2 cases for Klebsiella pneumoniae and one for Pseudomonas aeruginosa.
Mean time from the diagnosis of ARDS to methylprednisolone treatment was 11 Ϯ 2 days in the intermediate group (10 patients) and 21 Ϯ 8 days in the late group (9 patients). At the day of initiating corticosteroid therapy, all patients had bilateral infiltrates, 14 had P aO 2 / F IO 2 Յ 200 mm Hg, and 13 had quasistatic respiratory compliance Ͻ 20 mL/cm H 2 O. Two patients had P aO 2 /F IO 2 Ͼ 200 mm Hg and quasistatic respiratory compliance Ͼ 20 mL/cm H 2 O. At the same time, 18 out of 19 patients (94.7%) had a dead-space fraction Ͼ 0.55, whereas in the remaining one the dead-space fraction was 0.52. All patients were on volume controlled ventilation except one patient who was receiving pressure support ventilation on days 4 and 7 with a pressure support of 20 cm H 2 O and 5 cm H 2 O of PEEP.
We found no statistically significant differences in age, SAPS II, SOFA, and respiratory parameters between the intermediate and late groups ( Table 2 ). The late group showed a trend to having higher plateau pressure and lower compliance of the respiratory system than the intermediate group, without reaching significant statistical difference (see Table 2 ).
When comparing days 0, 4, and 7 after methylprednisolone treatment, we found an increase in the P aO 2 /F IO 2 ( Fig. 1) and compliance of the respiratory system, and a decrease in the physiological dead space (see Fig. 1 ), the P aCO 2 , the corrected V E , and the lung injury score, without differences in measured V E (Table 3) .
There were no statistically significant differences in duration of mechanical ventilation, ICU or hospital stay, or in-hospital mortality between the intermediate and late groups (Table 4) . Overall, 7 of 19 patients died (36.7%, 95% CI 15.8 -57.9%). Three of the 10 patients in the intermediate group and 4 of the 11 patients in the late group died (P ϭ .65).
Discussion
The main finding of our clinical study of patients with persistent ARDS was the improvement of pulmonary phys- iology parameters within 4 to 7 days after the initiation of corticosteroids therapy. These changes on pulmonary physiology were observed in both the intermediate and the late groups. However, the lack of a control group limits the applicability of our findings.
The main result was the decrease in the dead-space fraction in ARDS patients treated with corticosteroids. One could speculate that underlying mechanisms involve the potential improvement in lung inflammatory injury induced by corticosteroid therapy, which leads to a better ventilation-perfusion matching. This finally results in decreased dead-space fraction and V E requirements. This study shows results similar to those evaluating the effects of activated protein C therapy studies in ARDS patients. 19, 20 It highlights the potential usefulness of measuring deadspace fraction in ARDS patients as a tool to identify the patients who may benefit most from a particular therapeutic intervention and to evaluate the benefit of a treatment in the most severely ill patients, as supported by Nuckton et al. 5 Other interesting results of our study were that an increased physiologic dead-space fraction was characteristic of persistent ARDS in all cases. The improvement in P aO 2 /F IO 2 , compliance of the respiratory system, and lung injury score observed after 4 to 7 days of corticosteroids were consistent with the studies of the ARDS Network 7 and Meduri et al 18 that evaluated the efficacy of corticosteroids for persistent ARDS. The patients were included in the study with a P aO 2 /F IO 2 value Ͻ 200 mm Hg, as in the ARDS Network study, 7 or with a quasistatic respiratory compliance Ͻ 20 mL/cm H 2 O. This value is considered a very severe reduction and corresponds to a lung volume of 20% of the original healthy lung. 21 A dead-space fraction Ͼ 0.55 was defined as elevated, since this cutoff was associated with a significantly higher mortality during the acute and subacute phases of ARDS. 9 Of note, although in the subgroup of patients with late ARDS treated with corticosteroids, the dead-space fraction decreased in a similar magnitude to those with intermediate ARDS after corticosteroid treatment, the mean values were still Ͼ 0.55. The group with late ARDS presented a trend to having higher plateau pressure, corrected V E , and dead-space fraction, and lower quasistatic compliance than the intermediate group at day 0 (nonsignificant P value), probably due to a higher degree of pulmonary fibrosis.
The 37% mortality of our series of patients is somewhat higher than that observed in the ARDS Network study. 7 We found no statistical differences in terms of mortality between patients with corticosteroids therapy when initiated before or after 14 days of ARDS onset, in accordance with a recent meta-analysis that suggested that the reduction in mortality risk is not significantly affected by the timing of the treatment. 28 The effect on mortality of corticosteroids therapy in persistent ARDS remains controversial, 29 as shown by the results of 2 randomized studies. 7, 17 Despite our finding improvements in pulmonary physiology parameters in intermediate and late ARDS groups treated with corticosteroids, we believe that randomized controlled studies showing improvements in oxygenation and dead-space fraction, as well as survival or ventilation free-days, are needed before recommending corticosteroid therapy in these patients. The last is more difficult to demonstrate, 17 as occurred in the study of Liu et al, 19 where the improvement in oxygenation and deadspace fraction after activated protein C did not translate into improved survival.
The limitations of our study have to be acknowledged: we evaluated a low number of patients, and we had no control group, which is a major problem in the analysis of our results. However, while survival is the ultimate benefit and the outcome measure most often considered for critically ill patients, our interest was focused on physiological parameters. The pulmonary physiologic improvement with corticosteroids therapy allowed us to diminish the oxygen concentration supplied and the V E , and as a consequence of that we began the weaning process of mechanical ventilation earlier, altering the course of persistent ARDS.
Conclusions
In summary, this clinical study showed that the increase in oxygenation was accompanied by a decrease in the dead-space fraction after a few days of corticosteroids treatment in the intermediate and late groups. Potential benefit of corticosteroid therapy on physiological parameters and mortality or ventilation-free days will require an appropriately powered randomized placebo controlled trial.
